US Bancorp DE Sells 3,413 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

US Bancorp DE reduced its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 74.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,202 shares of the company’s stock after selling 3,413 shares during the quarter. US Bancorp DE’s holdings in Castle Biosciences were worth $32,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. Thrivent Financial for Lutherans boosted its holdings in Castle Biosciences by 58.0% in the third quarter. Thrivent Financial for Lutherans now owns 23,290 shares of the company’s stock worth $664,000 after purchasing an additional 8,552 shares during the last quarter. Quest Partners LLC grew its stake in shares of Castle Biosciences by 54.4% during the 3rd quarter. Quest Partners LLC now owns 4,318 shares of the company’s stock valued at $123,000 after purchasing an additional 1,522 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Castle Biosciences by 147.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 165,458 shares of the company’s stock valued at $4,719,000 after purchasing an additional 98,571 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Castle Biosciences in the 3rd quarter worth approximately $236,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Castle Biosciences by 16.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 274,761 shares of the company’s stock worth $7,836,000 after purchasing an additional 39,417 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Derek J. Maetzold sold 22,639 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $20.12, for a total value of $455,496.68. Following the sale, the insider now directly owns 80,465 shares of the company’s stock, valued at $1,618,955.80. This represents a 21.96 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Daniel Bradbury sold 7,867 shares of the company’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total value of $221,613.39. The disclosure for this sale can be found here. Insiders sold 44,204 shares of company stock valued at $1,055,988 in the last ninety days. Insiders own 7.20% of the company’s stock.

Castle Biosciences Stock Performance

Castle Biosciences stock opened at $20.49 on Wednesday. The company’s 50-day moving average price is $25.38 and its 200-day moving average price is $28.49. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a twelve month low of $16.97 and a twelve month high of $35.84. The company has a market cap of $573.86 million, a PE ratio of 102.46 and a beta of 0.98.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Robert W. Baird raised their price objective on Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. Stephens reissued an “overweight” rating and set a $41.00 price target on shares of Castle Biosciences in a report on Thursday, January 2nd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $40.00.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.